Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2Other hematologic neoplasm 1

Conditions

Myeloproliferative Disorders 5Myelodysplastic Syndromes 5Leukemia 5Myelodysplastic-Myeloproliferative Diseases 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Primary Myelofibrosis 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Thrombocythemia, Essential 1Precancerous Conditions 1Polycythemia Vera 1Multiple Myeloma 1Mastocytosis, Systemic 1Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1Hematologic Diseases 1Graft vs Host Disease 1Congenital Abnormalities 1Blast Crisis 1Anemia, Refractory 1Anemia 1

Interventions

Cyclophosphamide 62fludarabine phosphate 55Peripheral Blood Stem Cell Transplantation 44ruxolitinib 41Tacrolimus 41Busulfan 40Mycophenolic Acid 36Whole-Body Irradiation 32Antilymphocyte Serum 29Methotrexate 27Cyclosporine 27fludarabine 24Melphalan 19Filgrastim 19Radiotherapy 15Methylprednisolone 13thymoglobulin 12Stem Cell Transplantation 12Etoposide 12Cord Blood Stem Cell Transplantation 12Azacitidine 12Sirolimus 11Flow Cytometry 1011-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 10Psychiatric Rehabilitation 9Decitabine 9Specimen Handling 8Prednisone 8Cytarabine 8navitoclax 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Primary Myelofibrosis × Thalidomide × Myeloid × Clear all
NCT00274820 2020-07-27

Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder

Case Comprehensive Cancer Center

Phase 2 Completed
15 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelomonocytic, Chronic, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT00445900 2011-03-17

Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Mayo Clinic

Phase 2 Completed
22 enrolled
Myeloid

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡